<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pmed.1002882.t003" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pmed.1002882.t003</object-id>
 <label>Table 3</label>
 <caption>
  <title>Ongoing and planned TB clinical trials in children (as of December 2018).</title>
 </caption>
 <alternatives>
  <graphic id="pmed.1002882.t003g" xlink:href="pmed.1002882.t003" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Study/Trial Number</th>
     <th align="left" rowspan="1" colspan="1">Funding/ Sponsor</th>
     <th align="left" rowspan="1" colspan="1">Phase</th>
     <th align="left" rowspan="1" colspan="1">TB Type</th>
     <th align="left" rowspan="1" colspan="1">Purpose</th>
     <th align="left" rowspan="1" colspan="1">Design</th>
     <th align="left" rowspan="1" colspan="1">Regimen</th>
     <th align="left" rowspan="1" colspan="1">Study Population</th>
     <th align="left" rowspan="1" colspan="1">Location</th>
     <th align="left" rowspan="1" colspan="1">Status</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" colspan="10" rowspan="1">LTBI</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TBTC Study 35/NCT03730181</td>
     <td align="left" rowspan="1" colspan="1">TBTC, CDC</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Optimal dose, PK, and safety of 3HP for LTBI in HIV+/− children</td>
     <td align="left" rowspan="1" colspan="1">Open-label PK and safety trial of P and H coformulation</td>
     <td align="left" rowspan="1" colspan="1">P in fixed dose combination + H + P single formulation</td>
     <td align="left" rowspan="1" colspan="1">Infants and children (0–12 years old), 
      <bold>HIV+</bold>/−, modified age de-escalation, population PK modeling
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Accrual expected to start 2019</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT CS 5019</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">PK, safety, and tolerability of 1HP in HIV-infected and uninfected children with exposure to DS TB</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, open-label dose-finding and safety study</td>
     <td align="left" rowspan="1" colspan="1">1HP with integrase inhibitors in HIV-infected children</td>
     <td align="left" rowspan="1" colspan="1">Infants, children, and adolescents &lt;12 years old, 
      <bold>HIV+</bold>/−
     </td>
     <td align="left" rowspan="1" colspan="1">Multisite international</td>
     <td align="left" rowspan="1" colspan="1">Planned</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">iTIPS/NCT02613169</td>
     <td align="left" rowspan="1" colspan="1">Thrasher Research Fund</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of INH to prevent MTB in HIV-exposed uninfected infants</td>
     <td align="left" rowspan="1" colspan="1">Randomized control trial</td>
     <td align="left" rowspan="1" colspan="1">Daily H ×12 months versus no H</td>
     <td align="left" rowspan="1" colspan="1">Infants (6 weeks), HIV-exposed</td>
     <td align="left" rowspan="1" colspan="1">Kenya</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">P4v9 Trial/NCT00170209</td>
     <td align="left" rowspan="1" colspan="1">Canadian Institutes of Health Research</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy, safety, and tolerability of R and H for LTBI</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, open-label, randomized positive-controlled trial</td>
     <td align="left" rowspan="1" colspan="1">R ×4 months versus H ×9 months</td>
     <td align="left" rowspan="1" colspan="1">Children and adolescents (&lt;18 years), children with LTBI at high risk of TB</td>
     <td align="left" rowspan="1" colspan="1">Canada, Australia, Benin, Ghana, Guinea, Indonesia</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TB-CHAMP/ISRCTN92634082</td>
     <td align="left" rowspan="1" colspan="1">Joint Global Health Trials Scheme, South African MRC</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of Le for MDR TB prevention in HIV+/− child household contacts</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, cluster randomized, double-blind, placebo-controlled, superiority trial</td>
     <td align="left" rowspan="1" colspan="1">Daily Le ×6 months versus placebo</td>
     <td align="left" rowspan="1" colspan="1">Infants and children (0 to &lt;5 years old), 
      <bold>HIV+</bold>/HIV−, household randomization, IGRA+/−
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">V-QUIN/ACTRN12616000215426</td>
     <td align="left" rowspan="1" colspan="1">Australian National Health and MRC</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of Le for MDR TB prevention in adult and adolescent household contacts</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, randomized, double-blind placebo-controlled, superiority trial</td>
     <td align="left" rowspan="1" colspan="1">Daily Le ×6 months versus placebo</td>
     <td align="left" rowspan="1" colspan="1">Adolescents and adults, 
      <bold>HIV+</bold>/−, household randomization, TST+
     </td>
     <td align="left" rowspan="1" colspan="1">Vietnam</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">A5300B I2003B/NCT03568383 (PHOENIx)</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy and safety of De versus standard-dose H for MDR TB prevention in high-risk household contacts</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, open-label, randomized superiority trial</td>
     <td align="left" rowspan="1" colspan="1">Daily De ×26 weeks versus daily H + vitamin B6 ×26 weeks</td>
     <td align="left" rowspan="1" colspan="1">Adults, adolescents, children, infants, 
      <bold>HIV+</bold>/−, household randomization
     </td>
     <td align="left" rowspan="1" colspan="1">Botswana, Brazil
      <break/>Peru, India, Philippines, Haiti
      <break/>South Africa, Thailand, Kenya
     </td>
     <td align="left" rowspan="1" colspan="1">Planned to open 2019</td>
    </tr>
    <tr>
     <td align="left" colspan="10" rowspan="1">DS TB</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">DAtiC/NICHD069175
      <break/>NCT01637558
     </td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">I</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK of first-line TB drugs using 2010 WHO guidelines across pediatric populations</td>
     <td align="left" rowspan="1" colspan="1">Intensive PK sampling of HRZE</td>
     <td align="left" rowspan="1" colspan="1">ATT no ART, ATT + LPV/r-based ART; no ATT on LPV/r-based ART; ATT + NVP-based ART</td>
     <td align="left" rowspan="1" colspan="1">Children and infants (0–12 years), 
      <bold>HIV+</bold>/HIV−, malnutrition, drug–drug interactions, population PK modeling
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa, Malawi</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">OptiRif Kids</td>
     <td align="left" rowspan="1" colspan="1">TB Alliance, Unitaid</td>
     <td align="left" rowspan="1" colspan="1">I</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK, safety, and dose optimization of R for TB treatment in children and infants</td>
     <td align="left" rowspan="1" colspan="1">Intensive PK sampling</td>
     <td align="left" rowspan="1" colspan="1">High-dose R</td>
     <td align="left" rowspan="1" colspan="1">Infants and children (0–12 years old), HIV−</td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Treat infant TB</td>
     <td align="left" rowspan="1" colspan="1">TB Alliance, Unitaid</td>
     <td align="left" rowspan="1" colspan="1">I</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK and safety of first-line TB drugs using 2010 WHO dosing in infants</td>
     <td align="left" rowspan="1" colspan="1">Intensive PK sampling, first-line TB drugs, single-drug formulation</td>
     <td align="left" rowspan="1" colspan="1">Standard-dose HRZ</td>
     <td align="left" rowspan="1" colspan="1">Infants &lt;12 months, 
      <bold>HIV+</bold>/−
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT P1101/NCT01751568</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Safety and tolerability of raltegravir with R-containing TB regimen in infants and children</td>
     <td align="left" rowspan="1" colspan="1">Open-label, dose-finding, safety, tolerance, and PK study of raltegravir</td>
     <td align="left" rowspan="1" colspan="1">Chewable raltegravir tablets + 2NRTIs + R-containing TB regimen</td>
     <td align="left" rowspan="1" colspan="1">
      <bold>HIV+</bold>/TB-coinfected children (≥4 weeks to &lt;12 years old), received ≥1 week and ≤20 weeks of R-based TB therapy prior to ARV initiation
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">HIVPED001/NCT02348177</td>
     <td align="left" rowspan="1" colspan="1">AFD, MSF, AECID Spain; SDC</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Safety, tolerability, and virological effect of “superboosting” in HIV–TB-coinfected infants and children</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, open-label, nonrandomized, noninferiority PK study</td>
     <td align="left" rowspan="1" colspan="1">Super-boosted LPV/r (1:1) + R versus standard-boosted LPV/r (4:1) without R</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, (&gt;42 weeks old) 
      <bold>HIV+</bold>, clinical TB diagnosis
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa, Thailand, France</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TBM-KIDS/NCT02958709</td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Efficacy, PK, and safety of high-dose R +/− Le for TB meningitis in children</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">High-dose R + EHZ ×2 months/10HR versus high-dose R + LeHZ ×2 months/10HR versus standard of care (2REHZ/10HR)</td>
     <td align="left" rowspan="1" colspan="1">Children and infants (6 months–12 years), 
      <bold>HIV+</bold>/−, intensive PK, population PK modeling
     </td>
     <td align="left" rowspan="1" colspan="1">India, Malawi</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">SHINE study/ISRCTN63579542</td>
     <td align="left" rowspan="1" colspan="1">Joint Global Health Trials Scheme</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Efficacy and safety of shortened first-line TB regimen using 2010 WHO-recommended doses for minimal TB in children</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized, noninferiority trial</td>
     <td align="left" rowspan="1" colspan="1">2HRZ(E)/2HR versus 2HRZ(E)/4HR</td>
     <td align="left" rowspan="1" colspan="1">Children, adolescents, and infants (0–16 years old), 
      <bold>HIV+</bold>/HIV−, nested PK studies, drug–drug interactions
     </td>
     <td align="left" rowspan="1" colspan="1">India, Uganda, Zambia, South Africa</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">SURE-TBM/ISRCTN40829906</td>
     <td align="left" rowspan="1" colspan="1">MRC, DFID, NIHR, Wellcome Trust</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Efficacy and safety of high-dose R, Le, and H with Z for shortening TB meningitis treatment to 6 months</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized, noninferiority trial</td>
     <td align="left" rowspan="1" colspan="1">Higher dose (6RLeHZ) versus WHO standard of care regimen (2HRZE/10HR)</td>
     <td align="left" rowspan="1" colspan="1">Infants, children, and adolescents (28 days–15 years old), 
      <bold>HIV+</bold>/−
     </td>
     <td align="left" rowspan="1" colspan="1">Vietnam, India, Uganda, Zambia, Zimbabwe</td>
     <td align="left" rowspan="1" colspan="1">Planned</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">PK-PTB HIV01/
      <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01687504" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01687504</ext-link>
      <break/>
      <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01699633" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01699633</ext-link>
      <break/>
      <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01704144" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01704144</ext-link>
     </td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK and safety of WHO- recommended increased dosages of first-line TB drugs in children with TB and HIV/TB coinfection</td>
     <td align="left" rowspan="1" colspan="1">Open-label, steady-state PK study of first-line TB drugs and ARVs</td>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1">Children, infants (3–14 years old), 
      <bold>HIV+</bold>/−, drug–drug interactions
     </td>
     <td align="left" rowspan="1" colspan="1">Ghana</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Rifabutin PK trial</td>
     <td align="left" rowspan="1" colspan="1">ICMR, NACO</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK and safety of rifabutin</td>
     <td align="left" rowspan="1" colspan="1">PK and safety</td>
     <td align="left" rowspan="1" colspan="1">Rifabutin</td>
     <td align="left" rowspan="1" colspan="1">Adults, children, HIV−</td>
     <td align="left" rowspan="1" colspan="1">India</td>
     <td align="left" rowspan="1" colspan="1">Planned</td>
    </tr>
    <tr>
     <td align="left" colspan="10" rowspan="1">DR TB</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">MDR-PK 1</td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK, safety of second-line drugs for MDR TB, particularly Mo, Le, and Li</td>
     <td align="left" rowspan="1" colspan="1">Semi-intensive PK sampling, model-based analysis</td>
     <td align="left" rowspan="1" colspan="1">Ethionamide, Le, ofloxacin, Mo, high-dose H, PZA, terizidone, PAS</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, adolescents (&lt;18 years), 
      <bold>HIV+</bold>/HIV−, drug–drug interactions
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">MDR-PK2</td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK, safety of second-line drugs for MDR TB, particularly Mo, Le, and Li</td>
     <td align="left" rowspan="1" colspan="1">Semi-intensive PK sampling, model-based analysis</td>
     <td align="left" rowspan="1" colspan="1">Li, Mo, Le, clofamizine, BDQ</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, adolescents (&lt;18 years old), 
      <bold>HIV+</bold>/−, drug–drug interactions
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT P1108 NCT02906007</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK, safety, and tolerability of BDQ for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, single-arm, dose-finding and safety study</td>
     <td align="left" rowspan="1" colspan="1">BDQ ×24 weeks + routine background MDR therapy</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, adolescents (0–18 years old), 
      <bold>HIV+</bold>/−, population PK modeling, modified age de-escalation
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa, India, Haiti</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">232 and 233 NCT01856634 NCT01859923</td>
     <td align="left" rowspan="1" colspan="1">Otsuka</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK, safety, tolerability, and efficacy of De + MDR TB therapy in HIV−</td>
     <td align="left" rowspan="1" colspan="1">Open-label, single-arm dose-finding trial</td>
     <td align="left" rowspan="1" colspan="1">Multiple doses of De ×6 months + OBR</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, adolescents (0–17 years old), HIV−, population PK modeling, age de-escalation</td>
     <td align="left" rowspan="1" colspan="1">Philippines, South Africa</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT 2005 NCT03141060</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK, safety, tolerability of De + OBR for MDR TB in HIV+/− children</td>
     <td align="left" rowspan="1" colspan="1">Multisite, open-label, single-arm dose-finding trial</td>
     <td align="left" rowspan="1" colspan="1">De ×6 months + OBR</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, adolescents (&lt;18 years old), 
      <bold>HIV+</bold>/−, population PK modeling
     </td>
     <td align="left" rowspan="1" colspan="1">Botswana, India, South Africa, Tanzania</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Janssen C211 NCT02354014</td>
     <td align="left" rowspan="1" colspan="1">Janssen</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK, safety, tolerability of BDQ + OBR for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, open-label, single-arm, dose-finding and safety trial</td>
     <td align="left" rowspan="1" colspan="1">BDQ ×24 weeks + OBR</td>
     <td align="left" rowspan="1" colspan="1">Children, infants, adolescents (0–18 years old)
      <break/>HIV−, age de-escalation
     </td>
     <td align="left" rowspan="1" colspan="1">Russian Federation, South Africa, Philippines</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT 2020 “Smart Kids”</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety, efficacy of oral 6-month regimens for RR/ MDR/pre-XDR/XDR TB</td>
     <td align="left" rowspan="1" colspan="1">Multicenter, open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Oral 6-month regimen
      <break/>BDQ, De, Li, Le
      <break/>(clofazimine for FQ resistant)
     </td>
     <td align="left" rowspan="1" colspan="1">Infants, children, adolescents (0–15 years old), 
      <bold>HIV+</bold>/−
     </td>
     <td align="left" rowspan="1" colspan="1">Multisite</td>
     <td align="left" rowspan="1" colspan="1">Planned</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT P1106 NCT02383849</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS/DR</td>
     <td align="left" rowspan="1" colspan="1">PK and safety of R and H with NVP or LPV/r in low-birth-weight infants</td>
     <td align="left" rowspan="1" colspan="1">Open-label, nonrandomized PK study of ARVs and TB medicines</td>
     <td align="left" rowspan="1" colspan="1">NVP versus NVP + H versus NVP + H + R versus H alone or H + R versus LPV/r + 2NRTIs +/− H versus LPV/r + 2NRTIs + R +/− H</td>
     <td align="left" rowspan="1" colspan="1">Infants (7–14 days old), 
      <bold>HIV+</bold>/−, low birth weight, premature
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t003fn001">
   <p>IMPAACT trial protocols can be found at 
    <ext-link ext-link-type="uri" xlink:href="https://impaactnetwork.org/research-areas/tuberculosis.htm" xmlns:xlink="http://www.w3.org/1999/xlink">https://impaactnetwork.org/research-areas/tuberculosis.htm</ext-link>; NCT is the 
    <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov</ext-link> identification number; trials including HIV-infected (HIV+) persons are demarcated using bolded “HIV+” in the Study Population column.
   </p>
  </fn>
  <fn id="t003fn002">
   <p>Abbreviations: 1HP, 1 month of daily isoniazid and rifapentine; 3HP, 3 months of weekly isoniazid and rifapentine; AECID, Agencia Española de Cooperación Internacional para el Desarrollo (Spanish Agency for International Development Corporation); ART, antiretroviral therapy; ARV, antiretroviral; AFD, French Development Agency; ATT, antituberculosis therapy; BDQ, bedaquiline; CDC, Centers for Disease Control and Prevention; De, delamanid; DFID, British Department for International Development; DS, drug-sensitive; DR, drug-resistant; E, ethambutol; FQ, fluoroquinolone; H, isoniazid; HIV, human immunodeficiency virus; ICMR, Indian Council of Medical Research; IGRA, interferon gamma release assay; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trials Network; INH, isoniazid; Le, levofloxacin; Li, linezolid; LPV, lopinavir; LTBI, latent TB infection; Mo, moxifloxacin; MDR, multidrug-resistant; MRC, Medical Research Council; MSF, Médecins Sans Frontières; NACO, National AIDS Control Organization; NIAID, National Institute of Allergy and Infectious Diseases; NICHD, Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIH, National Institutes of Health; NIHR, National Institute for Health Research; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; OBR, optimized background regimen; P, rifapentine; PAS, P-aminosalicylic acid; PK, pharmacokinetics; PZA, pyrazinamide; R, rifampin; RR, rifampicin-resistant; SDC, Swiss Agency for Development and Cooperation; TB, tuberculosis; TBTC, Tuberculosis Trials Consortium; TST+, tuberculin skin test positive; WHO, World Health Organization; XDR, extremely drug-resistant; Z, pyrazinamide</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
